Halozyme Therapeutics HALO Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $312.01M+129% | $136.42M-67.5% | $419.67M+578% | $61.86M-64.9% | $176.33M+52.2% | ||
| $457.99M+7.4% | $426.27M+24.1% | $343.54M+9.0% | $315.07M+3.6% | $304.03M+5.5% | ||
| $14.84M-28.5% | $20.77M-29.8% | $29.6M-7.8% | $32.08M-4.1% | $33.44M-39.5% | ||
| $1B+21.5% | $825.21M-37.9% | $1.33B+18.4% | $1.12B-11.0% | $1.26B+16.3% | ||
| $46.93M+5.6% | $44.44M+9.5% | $40.58M+2.5% | $39.6M-1.5% | $40.22M-1.6% | ||
| $582.32M+0.3% | $580.36M+39.2% | $416.82M0.0% | $416.82M0.0% | $416.82M0.0% | ||
| $951.96M-3.0% | $981.47M+227% | $299.84M-5.6% | $317.61M-5.3% | $335.37M-16.5% | ||
| $2.67B+5.8% | $2.53B+13.7% | $2.22B+8.1% | $2.05B-6.5% | $2.2B+6.4% | ||
| $14.1M-32.5% | $20.9M+36.1% | $15.36M-17.8% | $18.69M-6.9% | $20.07M+95.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $363.21M+105% | $177.09M-78.8% | $837.23M+523% | $134.28M-10.7% | $150.38M+8.1% | ||
| $1.94B-9.6% | $2.14B+168% | $800.07M-47.0% | $1.51B+0.1% | $1.51B+0.1% | ||
| $2.45B-0.9% | $2.48B+44.2% | $1.72B-0.2% | $1.72B+0.4% | $1.71B+0.9% | ||
| 300M0.0% | 300M0.0% | 300M0.0% | 300M0.0% | 300M+243,802% | ||
| $204.84M+274% | $54.79M-89.1% | $502.15M+39.1% | $361.03M-24.5% | $477.96M+32.8% | ||
| $219.64M+350% | $48.81M-90.3% | $503.92M+51.4% | $332.75M-31.0% | $482.27M+32.6% | ||
| $2.67B+5.8% | $2.53B+13.7% | $2.22B+8.1% | $2.05B-6.5% | $2.2B+6.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Halozyme Therapeutics's total assets?
- Halozyme Therapeutics (HALO) holds $2.7B in total assets, up 21.7% year over year.
- How much debt does Halozyme Therapeutics have?
- Halozyme Therapeutics carries $2.2B in total debt against $219.6M of shareholders' equity, a debt-to-equity ratio of 9.91.
- How much cash does Halozyme Therapeutics have?
- Halozyme Therapeutics holds $312.0M in cash and equivalents.
- Can Halozyme Therapeutics cover its short-term obligations?
- Its current ratio is 2.76 — current assets exceed current liabilities.
- Where does Halozyme Therapeutics's balance sheet data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
